- Home
- API vs CVRX Comparison
API vs CVRX Comparison
Compare API & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- CVRX
- Stock Information
- Founded
- API 2013
- CVRX 2000
- Country
- API United States
- CVRX United States
- Employees
- API N/A
- CVRX N/A
- Industry
- API Computer Software: Prepackaged Software
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- API Technology
- CVRX Health Care
- Exchange
- API Nasdaq
- CVRX Nasdaq
- Market Cap
- API 383.0M
- CVRX 419.8M
- IPO Year
- API 2020
- CVRX 2021
- Fundamental
- Price
- API $4.80
- CVRX $17.62
- Analyst Decision
- API Strong Buy
- CVRX Strong Buy
- Analyst Count
- API 1
- CVRX 7
- Target Price
- API $6.00
- CVRX $17.00
- AVG Volume (30 Days)
- API 829.5K
- CVRX 213.8K
- Earning Date
- API 02-24-2025
- CVRX 01-27-2025
- Dividend Yield
- API N/A
- CVRX N/A
- EPS Growth
- API N/A
- CVRX N/A
- EPS
- API N/A
- CVRX N/A
- Revenue
- API $134,844,000.00
- CVRX $47,255,000.00
- Revenue This Year
- API N/A
- CVRX $31.78
- Revenue Next Year
- API $5.50
- CVRX $26.42
- P/E Ratio
- API N/A
- CVRX N/A
- Revenue Growth
- API N/A
- CVRX 34.38
- 52 Week Low
- API $1.65
- CVRX $6.40
- 52 Week High
- API $6.64
- CVRX $29.23
- Technical
- Relative Strength Index (RSI)
- API 56.63
- CVRX 76.79
- Support Level
- API $3.54
- CVRX $13.82
- Resistance Level
- API $3.98
- CVRX $17.72
- Average True Range (ATR)
- API 0.31
- CVRX 0.88
- MACD
- API 0.05
- CVRX 0.49
- Stochastic Oscillator
- API 91.78
- CVRX 98.09
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.